This is a post-market clinical follow-up, retrospective chart review of MIMS® surgical procedures conducted during time period between Sep 2023 and May 2025.
Study Type
OBSERVATIONAL
Enrollment
40
The MIMS® procedure uses the proprietary MIMS® device, which creates a sclerostomy in the eye.
S. Malayan Eye Center
Yerevan, Armenia
Change in IOP from medicated baseline at 12 months post-MIMS® surgery
Time frame: Medicated baseline at 12 months post-MIMS® surgery
Change in the number of topical IOP-lowering medications from medicated baseline at 12 months post-MIMS® surgery
Time frame: Medicated baseline at 12 months post-MIMS® surgery
Success rate at 12 months post-MIMS® surgery
Time frame: 12 months post-MIMS® surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.